Peptic ulcer has been a disease of animals and humans since the acid-producing organs were the means of preparing food for absorption. In mammals, digestion and passage of food to be absorbed in the intestines was enabled by acid-producing organs that had specialized epithelial cells, musculature and innervation. On the path through the history of civilization, we can observe views and perspectives of food digestion that were introduced by contemporary philosophers, physicians, experts and scientists, differing from the era of agriculture, over the era of industrialization to modern times of electronic technology and computers.
Hippocrates (5th century BC) ( fig. 1 ) introduced the term of pepsys to denote that the food was 'cooked' and converted to four humors: blood, phlegm, yellow and black bile [1] . This view prevailed for nearly 2,000 years, a time span in which almost nothing was done to clear the mystery of food digestion in the stomach. Theophrastus Bombastus von Hohenheim (Paracelsus, 1493-1541), a professor of medicine in Basel who also taught in Freiburg and Strasbourg, believed that human diseases were caused by chemical changes governed by chief archeus that represented the ultimate forces of energy that governed the universe [2] . Thus, the historic path to modern gastroenterology represented a long way from these early philosophical observations, over the identification of gastric acidity and studies of gastric function in the 19th century to Ismar Boas , the founder of gastroenterology as a specialty and the editor of the first medical journal for digestive diseases.
It is almost an impossible task to describe the whole history of concepts in gastric pathophysiology and discoveries in etiopathogenesis of peptic ulcer disease (PUD), mentioning the single role of each anatomist, physiologist, researcher or clinician who contributed to revealing the mechanisms of gastric acid secretion and therapy of acidrelated diseases. The authors have tried to point out the most important steps in understanding the workings of the stomach -from early ideas to modern concepts of molecular mechanisms of gastric acid secretion and mucosal protection in order to diagnose and treat PUD ( table 1 ) .
Pathophysiological Concepts in Gastric Acid Secretion
With regard to the role of nerves in gastric acid secretion, it was A. Vesalius (1543) who described vagal nerves, 'wandering' to different abdominal organs and structures [3] . The story of gastric acid secretion had begun with early ideas on gastric secretion and process of digestion, described by Lazzaro Spallanzani (1729-1799), the Italian physiologist, and René de Réaumur (1683-1757), the French scientist. After series of experiments conducted on animals and himself, Spallanzani proposed his 'theory of chemical solution' (1784) by which the solvent called 'gastric juice' (1793) was entirely neutral [4] . In contrast, de Réaumur concluded (1752) that gastric juice was acidic [5] . He conducted the experiments on a buzzard, a prey bird that was known to eject indigestible food from its stomach, and his experiments showed that the juice extracted from regurgitated pieces of sponge out of the buzzard's stomach were capable of digesting meat. The experiments of de Réaumur paved the way for William Prout, the English physiologist who provided the chemical analysis, showing that gastric juice contained acidtermed 'muriatic acid' -that was later identified to be hydrochloric acid [6] .
The first descriptions of gastric physiology of food digestion were made by the French scientists Dupuytren and Bichat (1801) in Paris, who observed gastric fistula of Madeline Gore, after she fell down stone stairs at age 20 years, and William Beaumont, the US army surgeon who studied Alexis St. Martin's gastric fistula (1823-1833), acquired after a gunshot wound, in 1822 [7] . During the 19th and early 20th century, the investigation of the morphology and fine structure of the stomach answered the question of the source of gastric acid: Johannes Purkinje gave the first description of gastric glands and principal cell types (light microscopy, 1837), Camillo Golgi noted the marked change of glands and parietal cells by digestive stimulus (1893-1895) and Dalton and colleagues [8, 9] documented the fine structure of gastric epithelial cells, including parietal cells (1951) ( fig. 2 ) .
Almost paralleling the investigations of stomach glands' morphology and the acidic nature of gastric juice were the studies on physiological concepts of gastric secretion in the late 19th and early 20th century. In St. Petersburg, I.P. Pavlov was the first to demonstrate that gastric acid secretion in fasted dogs starts following exposure to appetizing food even without the passage of this food into the stomach, using esophageal and gastric fistulas in dogs ('sham feeding', 1895) [10] . For his theory of 'nervism' -the neuro-reflex stimulation of digestive secretion by nervus vagus -he was awarded the Nobel Prize in 1904. The works of L. Popielski, a Polish pharmacologist at Lvov University (1920), and C.F. Code (1956) revealed the histamine-mediated concept of gastric secretion, as an alternative to 'nervism' [11, 12] . The discovery of gastrin by J.S. Edkins (1905) and its isolation and synthesis by R. Gregory and H. Tracy (1964) was followed by experiments of B. Uvnäs and L. Olbe, demonstrating the role of gastrin in acid secretion by the fact that removal of gastric antrum -the major source of gastrin -greatly attenuated gastric secretory response to sham feeding [13] [14] [15] . Theodor Schwann in Berlin described a watersoluble factor in gastric juice that was capable of digesting egg white (1836), and he called it 'pepsin', after the Greek word for digestion [16] . The possible existence of a proenzyme, pepsinogen, was formally postulated by Epstein and Grützner (1854) and, in a series of publications (1879-1882) J.N. Langley at Cambridge established the basic morphology and secretory characteristics of the pepsinforming glands in the stomach that contained pepsinogen [17] . Langley also coined the term 'oxyntic' to identify the role of the acid-secreting cells in gastric mucosa. R.P. Heidenhain, a professor of physiology in Breslau, continued the study of pepsin (1878) and also described a 'third' type of cells, which adhered to the external surface of epithelial cells, that 100 years later would be identified as enterochromaffin-like cells, responsible for biosynthesis of histamine [18] . These discoveries have shown that gastric acid and pepsin are essential for the process of food digestion in the stomach, and also pointed to histamine, being the most potent gastric acid secretagogue and final common chemostimulator of oxyntic cells. In addition, it was found that histamine is released from enterochromaffin-like cells upon stimulation by food and other gastric secretagogues, such as gastrin. However, there existed the unresolved questions of regulation and mechanisms of acid secretion or 'how does it happen', and rietal cell mass [19] . Gerhard Katsch of Greifswald introduced quantitative function tests with caffeine/histamine in order to evaluate gastric secretory capacity for hydrochloric acid (1925) [20] . By the 1960s a long list of antihistaminic agents had been proposed and studied, without identification of an agent effective in the inhibition of acid secretion.
Following the pioneering work of Sir Henry Dale in the isolation and function of histamine, Sir James Black, a pharmacologist working for Smith Kline & French in England, proposed that there existed a homogenous population of non-H 1 receptors in gastric mucosa that he chose to term 'H 2 ' receptors, and announced that compound burimamide (1972), which possessed an imidazole ring with side chain, was capable of inhibiting the secretion of gastric acid [21] . These new H 2 -receptor antagonists were found to inhibit histamine-induced gastric secretion, as well as the gastric secretion provoked by meal or vagal excitation [22] . The development of the concept of H 2 -receptor antagonists and their therapeutic utility was a major factor for Sir James Black to be awarded the Nobel Prize for Medicine or Physiology in 1988.
Still, the key question was unanswered: How does the stimulation by vagal nerves, gastrin or histamine, acting via the membrane receptors and intracelullar mediators, provoke gastric acid secretion? The experiments on bullfrog oxyntic cells by A.L. Ganser and J.G Forte in the USA were able to demonstrate the existence of a unique enzyme in the parietal cell: a potassium-stimulated adenosine triphosphatase (K + -ATPase) which was later identified, also in mammals and humans, as the final step in acid secretion -the acid pump [23] . In studies that followed, G. Sachs and coworkers elucidated that there are about 1 billion (10 9 ) parietal cells in the healthy stomach, being characterized by a large number of mitochondria that provide ATP to drive the acid secretion process, and having tubulovesicles and secretory canaliculi as well. They also showed that upon activation of parietal cells, much of the tubulovesical membrane is inserted into the secretory canalicular membrane, carrying with it many acid pumps and greatly increasing acid secretion by activation of the proton or acid pump (H + ,K + -ATPase): for each H + ion pumped out of the cell, a K + ion is pumped in, resulting in a significant pH gradient -from pH 7.3 inside the parietal cell cytosol to pH 1.0 in the secretory canaliculi [24] . When the parietal cell is stimulated, an increase in permeability of the apical membrane for chloride (Cl -) ions occurs and diffusion of chloride ions into secretory canaliculi takes place, but unlike K + ions, the chloride ions are not pumped back into the parietal cell [24] . The discovery of location, nature and molecular structure of the acid pump led to the development of products that acted directly on the acid pump: CMN 131 (pyridylmethylthioacetamide) in 1971 and its derivative timoprazole in 1974, picoprazole in 1976 and ultimately to omeprazole in 1979 [25] . Omeprazole is a pro-drug and a weak base with high affinity for acidic space close to the acid pump where it is rapidly converted into sulfenamide, which forms a covalent complex with the acid pump enzyme that results in effective acid inhibition, irrespective of the type of stimulus acting on the parietal cell [26] . Following the first discoveries, the human energy and resources of many pharmaceutical companies were focused on the development of compounds that would rapidly and effectively act on acid pump enzyme, outlining the group of potential proton pump inhibitors (PPIs), of which many were thrown on the healthcare market and have been used for treatment of patients with acid-related disorders.
Discoveries in Etiopathogenesis of Mucosal Injury and Peptic Ulcer Disease
Dragutin (Carl) Schwarz (Varazdin, Croatia 1868 to Vienna, Austria 1917) was the unique figure in clinical research with regard to the role of gastric acid in etiopathogenesis of PUD. With his works as a surgeon, he contributed to surgical therapy and pathology of penetrating gastric ulcer [27] . However, with regard to the historical impact to drive research in PUD, Schwarz has been remembered for his famous dictum: 'No acid, no ulcer' ('Ohne saueren Magensaft kein peptisches Geschwür ', 1910) , that has strongly influenced peptic ulcer research to the present day [28] .
At the beginning of the 20th century, it was believed that the stomach wall harbors an intrinsic property that was capable of resisting digestion with gastric acid, the so-called 'vital spirit', and that the breakdown of such a vital force is responsible for mucosal damage and ulcer formation [29] . In the early 1930s, T. Teorell [30] proved that surface epithelial cells and adherent mucus containing bipolar phospholipids prevent the ionized mineral acids, such as hydrochloric acid, from back-diffusing from gastric lumen into the mucosa, due to the high polarity of phospholipids. On the contrary, the unionized organic compounds, such as bile salts or aspirin, with a relatively low pKa, can rapidly reach surface mucosal cells by nonionic diffusion to accumulate in their interior, dissociate in neutral surroundings and to cause mucosal damage [30] . These observations suggested that mucosal injury occurs regularly, but does not lead to clinically significant disruption of the function, implicating that 'mucosal defense' consists of several components or 'layers', with secondary components becoming more important when more superficial components are breached. H. Davenport and C. Code are responsible for coining the term 'gastric mucosal barrier ' (1955) , and together with J.F. Scholer they proposed that breaking of the barrier represents the initial step in the process of mucosal injury [31, 32] .
Until the 1970s, peptic ulcer was believed to be the result of corrosive effects of gastric acid, and in the 1980s and 1990s the term of 'mucosal defense' was delineating various factors and components that permit the gastric mucosa to remain intact despite its frequent exposure to substances with a wide range of temperatures, pHs, and osmolarities, as well as to substances with detergent or cytotoxic action, and bacterial products capable of causing local and systemic inflammatory reactions [33] . The works of J.R. Vane and A. Robert documented that prostaglandins (a group of fatty acids first isolated from seminal fluids by Von Euler, in 1936) modulate virtually every aspect of gastric mucosal defense [34] . Vane, who was later awarded the Nobel Prize, described the finding that aspirin and other NSAIDs inhibited the synthesis of prostaglandins in the gastric mucosa (1971), and Robert (1976) documented that prostaglandins in doses well below those necessary for inhibiting gastric acid secretion showed the protective effect against oral administration of necrotizing agents [35, 36] . Later on, the prostaglandins were shown to influence the major components of the gastric mucosal barrier: they maintain the integrity of epithelium and mucosal blood flow, also being the potent inhibitors of leukocyte adherence to endothelium in mucosal inflammation, as well as the promoters of ulcer healing. They enhance bicarbonate and mucus secretion and decrease gastric mucosal barrier permeability and acid back-diffusion [37] . This remarkable ability of prostaglandins to reduce gastric mucosal injury was described with the term 'cytoprotection' that was coined by A. Robert after the suggestion of E. Jacobson.
Beginning in the latter half of the 19th century, the studies on gastric bacteriology that followed paved the way for the discovery of the association between Campylobacter (Helicobacter) pylori and peptic ulcers by Robin Warren (1979) and Barry Marshall (1982). The German scientist G. Böttcher and French scientist M. Letulle demonstrated bacterial colonies in the ulcer floor and its mucosal margins (1875), being the first to postulate the causation of ulcers to the bacteria which they could demonstrate, followed by W. Jaworski in Cracow, who discovered and postulated a pathogenic role for the spiral organism ( Vibrio rugula ) he found in gastric contents (1896), and I. Boas in Berlin, who co-discovered the Oppler-Boas bacterium, which he thought was implicated in the etiology of gastric carcinoma [38] . Almost paralleling the research of gastric bacteria, the importance of the vagal nerve in gastric pathophysiology was widely accepted, especially after Dragstedt's pioneering work on the role of vagotomy in the treatment of peptic ulcers [39] . Interestingly, in his first paper that was published in 1917, in the same year when C. Schwarz died in Austria, Dragstedt described the bacterial model of gastric and duodenal ulcers, revealing the possibility of growing bacteria from these ulcers [40] . Further studies of A. Kussmaul (1869) Gorham (1940s) were all speaking of bacteria in the stomach that subsequently led to the study of E.D. Palmer on gastric samples from 1,180 subjects, using standard histological techniques (1950s) that failed to demonstrate the presence of bacteria in the stomach [38] . Palmer concluded that the results of all previous authors were the sequels of post-mortem colonization of the gastric mucosa with oral cavity organisms.
Robin Warren, a pathologist at the Royal Perth Hospital, and a young gastroenterology fellow, Barry Marshal, described the association of the S-shaped Campylobacterlike organism and histological changes in 135 gastric biopsy specimens (1983) , and by fulfilling the requirements of four of Koch's postulates demonstrated the infectious nature of provoked gastritis [41] . With this discovery began the modern Helicobacter era leading to the fact that H. pylori represents a major etiopathogenetic factor for gastroduodenal pathology: acute and chronic gastritis, peptic ulcer, gastric cancer and MALT lymphoma. The notion that the prevalence of H. pylori-associated gastritis and its sequels should be regarded as an infectious disease led to worldwide major interventions, such as use of antibiotics in eradication therapy for H. pylori and attempts in vaccine development, as well.
Old and New Therapies: Modalities of Acid Inhibition
Beside chalk and pearl juleps, throughout the 17th and early 19th century there was no record on specific remedies for gastric diseases. Cruveilhier in Paris had written extensively on the pathology of PUD, but in those times little specific therapy apart from dietary adjustments or homeopathic remedies were apparent. Glycyrrhetinic acid, a constituent of liquorice, was used as a folk remedy for PUD, and in the latter half of the 19th century physicians were treating peptic ulcer by using the extract of belladonna, containing atropine, a non-selective muscarinic antagonist with intolerable side effects, such as blurred vision, dry mouth and bladder dysfunction [42] . B. Sippy (1915) and R. Doll introduced bland diets in the treatment of patients with peptic ulcer, augmented with the addition of neutralizing compounds and antacids. However, such regimens led to a significant decline in quality of life and significant side effects that even surgery became a reasonable option [43] .
A surgical approach to peptic ulcer had been confounded for years by the problems related to sepsis and lack of anesthesia, problems of perioperative morbidity and mortality, as well as the problems of 'post-gastrectomy syndromes'. Nevertheless, the resection procedures, devised by Billroth (1881), Pean, Moynihan and Ridiger, were capable of removing the ulceration, also providing relief of pain, bleeding, perforation and stenosis. However, alternative strategies to decrease secretion of acid were developed: M. Jaboulay in France performed the first vagotomy in a human patient (late 19th century), later combining vagotomy with a gastrojejunostomy to promote gastric emptying, followed by M.A. Latarjet in Lyon (1921) and L. Dragstedt (1943) in Chicago [44] .
Antacids, protective agents, anticholinergics, and later gastrin antagonists and prostaglandins were used for decades in the treatment of peptic ulcer, with differing effects. The advent of the concept of H 2 -receptor antagonists in the late 1970s denoted the end of the 'before cimetidine' era, due to the results of clinical studies that documented that these drugs were effective for pain relief of ulcer pain and for ulcer healing, as well as in continued use being effective in reducing ulcer recurrence [45] . A standard single dose of an H 2 antagonist taken at bedtime (e.g. cimetidine 800 mg, ranitidine 300 mg, famotidine 40 mg, or nizatidine 300 mg) would be expected to heal about 80% of duodenal ulcers after 4 weeks, a proportion that increases to 95% after a total of 8 weeks [46] . Healing of gastric ulcers with H 2 receptors usually takes longer: 65-70% after 4 weeks and 85-90% after 8 weeks [47] . However, the development of pharmacologic tolerance to all available H 2 antagonists in prolonged therapy had been observed in the early 1990s, especially limiting the use of these drugs in maintenance therapy for acid-related disorders [48] .
The PPIs (the irreversible inhibitors of the enzyme H + ,K + -ATPase) were associated with higher rates and faster duodenal ulcers healing (90% after 4 weeks), as well as higher rates and faster gastric ulcers healing (approximately 90% after 4 weeks), providing a greater degree of inhibition of gastric acid secretion than did conventional doses of the H 2 antagonists [49] . In addition, PPIs have been proven to be a successful treatment in patients with Zollinger-Ellison syndrome, and in healing of gastric ulcers in patients who continue to use NSAIDs [50] . Noteworthy, inhibition of acid secretion with PPIs is never complete because new molecules of acid pumps are constantly being synthesized, and therefore PPIs do not induce achlorhydria [51] . Early concerns with regard to formation of carcinoid tumors, derived from enterochromaffin-like cells in rats on prolonged use of high doses of PPIs, had not been encountered in routine clinical use of PPIs [52] . Thus, H 2 antagonists had been proven to be more effective in inhibiting acid secretion in the basal state (fasting or overnight) than in response to food digestion, and PPIs offered a strong reduction of basal and stimulated acid output, being effective in maintaining gastric juice at pH 1 3 to 1 5, lasting 8-16 h, and providing optimal treatment for acid-related disorders [53] .
Role of Endoscopy
The low prevalence of peptic ulcer that had been documented during the 19th century may be attributed to an inability at the time to diagnose uncomplicated peptic ulcer during the patient's life: the statistics were mostly based on autopsy studies [54] . Adolf Kussmaul (1822 Kussmaul ( -1902 at the University of Freiburg performed the first gastroscopy ever (1868), by introducing his endoscope into the stomach of the sword swallower [55] . Nevertheless, from 1910 to 1970, the methods of radiology were superior to endoscopy in diagnosing peptic ulcer. Using the side-viewing endoscope, devised by Elsner (1910/1911), Rudolf Schindler successfully performed gastroscopies that resulted in his first published book on gastroscopic diagnosis ('Lehrbuch und Atlas der Gastroskopie', 1923) [56] . In 1932, Schindler introduced the semiflexible WolfSchindler gastroscope into clinical practice, but there was still a problem with difficulty of passage, limitations of viewing, and continuing risk of injury [57] . In 1954, the discoveries of image transmission through a flexible bundle of oriented glass fibers -termed a 'fiberscope' -by Hopkins and Kapany, followed by the development of Hirschowitz's prototype of the first fiberscope for clinical use (1957), enabled the commercial production of gastroduodenal fiberscope by American Cystoscope Makers, Inc. (ACMI), in 1960 [58] . Since the 1970s, endoscopy has been the gold standard for diagnosing ulcer, healing and relapse in a multitude of clinical trials of ulcer treatment. Further development of electronic video technology enabled the advent of videoendoscopy (Welch-Allyin Inc., 1983) that revolutionized the methods of teaching in gastrointestinal endoscopy [59] .
Nowadays, we have witnessed new techniques and methods of endoscopy and endosonography that have been brought into clinical practice, highlighting the possibility of imaging beyond white light and beyond mucosal layer, as well.
Society and Healthcare
The burden of peptic ulcer in society may be outlined by its association with the prevalence of H. pylori in a certain population, the prevalence of comorbid conditions and chronic medication, as well as other risk factors, making the patients prone to the development of peptic ulcer. Nevertheless, the lifetime risk for peptic ulcer in patients with H. pylori infection is 3-25%, the overall risk being greater in NSAID users (OR 6.1) than in NSAID users without H. pylori infection (OR 4.8) [60] . There has also been some data pointing to the possible association of peptic ulcer to other conditions with a significant impact on society: anxiety disorder (OR 3.43), panic disorder (OR 3.11), dysthymia (OR 3.59) and bipolar disorder (OR 2.91) [61] . However, nicotine and alcohol dependence seem to play a substantial role in explaining the link of these disorders to PUD. Interestingly, Italian authors even observed a significant reduction in sperm motility with increased systemic levels of TNF-␣ in CagA-positive infertile patients with H. pylori infection, but it seems these results need further clarification [62] .
Peptic ulcer remains a common condition, although the reported incidence and prevalence is decreasing, and this decrease may be due to a decrease in H. pylori-associated PUD [63] . However, the 1-year prevalence of peptic ulcer has been reported ten times greater in patients aged 75-84 years (0.40%) than in patients aged 0-35 years (0.04%) [64] . A Danish study reported a decrease of overall incidence of peptic ulcer that was accompanied by an increase of peptic ulcers potentially related to NSAID use from 39% in 1993 to 53% in 2002 (p ! 0.01), and a study from the Netherlands documented that admission rates for complications of PUD remained fairly stable in men and increased slightly in women, over the period 1980-2003 [65, 66] . In the USA (2004), peptic ulcer was a firstlisted diagnosis at hospital discharge in 37% of cases, and nearly 80% of deaths related to peptic ulcers occurred among people aged 6 65 years [67] . With regard to total costs of digestive diseases in the USA (2004), the total costs of both PUD and gastroesophageal reflux disease were leveling to about 60% of total costs for all digestive cancers and, interestingly, PPIs represented 50.6% of prescriptions and 77.3% of costs of retail pharmacy sales for all digestive diseases [67] . Worldwide, peptic ulcer and its complications thus remain the cause of significant morbidity, especially in older age groups, representing a major burden for ambulatory and hospital healthcare resources. Never to be forgotten, all our efforts as gastroenterologists have been intended for the well-being of our patients, throughout their journey in the circles of diagnosis and treatment ( fig. 3 ). If it is not possible to cure the disease entirely, our task is the improvement of the patient's health-related quality of life.
Conclusions and 'A View to the Future'
Being an interface to the 'outer world', the gastroduodenal mucosa has been under constant attack during the era of human civilization, and its homeostasis is essential for living a healthy life. The history of medicine has taught us that gastric acid secretion plays a major role in the pathophysiology of PUD. During the past 50 years we have witnessed major discoveries in etiopathogenesis of PUD, as well as the advent of potent acid inhibitors and advances in methods and techniques of upper gastrointestinal endoscopy. Just to mention a few, the open questions that remain are 'do we need a special approach for cohorts of patients who are at special risk for PUD' and 'do we need more powerful/prolonged acid inhibition.' Maybe the study of genetics and epigenetics would lead to improved protocols for eradication of H. pylori infection and to effective prevention of gastric atrophy. Looking back, we should realize that there is at least as much to learn in front of us as there was behind.
